An investigation into the prediction of the plasma concentration-time profile and its inter-individual variability for a range of flavin-containing monooxygenase substrates using a mechanistic physiologically based pharmacokinetic modelling approach

Data Supplement

• Supplemental Data -

  Supplementary Table 1 - Human in vitro data for FMO substrates (Jones et al., 2017)
  

  Supplementary Table 2 - Options used to define the elimination within PBPK platform (Simcyp V16)
  

  Supplementary Figure 1 - Forest plot showing the physiologically based pharmacokinetic modeling performance of FMO substrates using rFMO data with and without scalar (tissue specific or ISEF) in the model
  

  Supplementary Table 3 - Simulated mean (SD) PK parameters for FMO substrates using HLM or rFMO with ISEF or tissue specific scalar data
  

  Supplementary Table 4 - Paediatrics simulations for Itopride using rFMO data
  

  Supplementary Table 5 - Mass Spectrometer parameters for FMO substrates
  

  Supplementary Text